Dr. Ami Sabharwal

Dr. Ami Sabharwal is a consultant oncologist with a special clinical interest in non-surgical management of prostate and bladder cancers using advanced radiotherapy techniques, brachytherapy, hormone therapies, drug therapies and radionucleotides.

Dr Sabharwal trained in London and Oxford, becoming a Consultant Oncologist in Oxford in 2009; giving her a wealth of experience as a consultant over the last 12 years treating patients with excellent outcomes.

Ami has a specialist interest in treating urological cancers, primarily with targeted radiotherapy (IMRT and IGRT), as well as low dose rate brachytherapy and with systemic agents (hormones, chemotherapy, biological and radionucleotide therapies). She is an advocate for patient centred care (clear communication, patient choice and informed consent), understanding the need for individualised treatment.

Dr. Sabharwal is active in the field of research, acting as Principle Investigator in a a number of Phase 3 clinical trials. She was Governance lead (2010-19) for Oncology (including Radiotherapy) and in addition Oncology Morbidity and Mortality chair at the Oxford University Hospitals NHS Foundation Trust.

• Intensity modulated radiotherapy (IMRT)
• Image guided radiotherapy (IGRT)
• Radiotherapy
• Brachytherapy (ARSAC holder for Iodine-125)
• Chemotherapy
• Immunotherapy
• Hormone therapy
• Radionucleotides (ARSAC holder for Radium-223)

• Prostate Cancer
• Bladder Cancer